Chemomab Therapeutics Ltd. (CMMB) Financial Statements
Free cash flow over the same period: -$8.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CMMBChemomab Therapeutics Ltd.Follow CMMB — free
—
Price chart with a free account
- Market cap
- 7.5M
- P/E TTM
- 1.1
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 24 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Research & development | 13.3 | 4.7 | 6.3 | 17.0 | 18.4 | 11.3 | 5.8 | — | |
| Operating income | — | — | — | — | — | -103.0 | -112.0 | — | |
| Pre-tax income | 27.1 | 6.0 | -12.5 | -28.2 | -24.2 | -13.9 | -9.0 | -7.6 | |
| Income tax | 0.0 | 0.0 | 0.0 | -0.5 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net income | -27.1 | -6.0 | -12.5 | -27.6 | -24.2 | -13.9 | -9.0 | -7.6 | |
| Diluted EPS ($) | 0.79 | 0.04 | 0.06 | -0.12 | -0.10 | -0.04 | -0.02 | 0.01 | |
| Diluted shares (mn) | — | — | — | 227.6 | 235.0 | 359.0 | 510.2 | — |
USD millions · SEC XBRL
Chemomab Therapeutics Ltd. — questions
- What is Chemomab Therapeutics Ltd.'s net income?
- -$7.6M over the twelve months to 2026-06-30.
- What is Chemomab Therapeutics Ltd.'s free cash flow?
- -$8.7M over the twelve months to 2026-06-30.
- What are Chemomab Therapeutics Ltd.'s diluted earnings per share?
- $0.01 over the twelve months to 2026-06-30.
Every figure on this page comes from Chemomab Therapeutics Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.